Akebia Therapeutics Resubmits New Drug Application To FDA For Vadadustat
Portfolio Pulse from Benzinga Newsdesk
Akebia Therapeutics has resubmitted its New Drug Application (NDA) to the FDA for Vadadustat, a treatment for anemia due to chronic kidney disease.
September 28, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akebia Therapeutics' resubmission of its NDA for Vadadustat to the FDA could potentially lead to a positive impact on its stock price if the application is approved.
The resubmission of the NDA for Vadadustat indicates that Akebia Therapeutics is making progress in getting the drug approved. If the FDA approves the application, it could lead to increased revenues for the company, which would likely have a positive impact on its stock price.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100